| abstract |
The present invention relates to a rapamycin target protein (mTOR) kinase dependent disease, particularly a cancer disease, comprising (a) a phosphoinositide 3-kinase inhibitor compound of formula (I) and (b) an mTOR inhibitor. Pharmaceutical combination; Pharmaceutical composition containing the combination; Use of the combination for the preparation of a drug for the treatment of proliferative diseases; Use of the combination as a combined preparation for simultaneous, separate or sequential use A commercial package or product comprising; and a method for treating warm-blooded animals, particularly humans. |